1. Introduction
1.1 Business Market Insights Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:
4. South and Central America RNAi Therapeutics Market Landscape
4.1 Market Overview
4.2 Porter's Five Forces Analysis
- 4.2.1 Bargaining Power of Suppliers
- 4.2.2 Bargaining Power of Buyers
- 4.2.3 Threat of New Entrants
- 4.2.4 Competitive Rivalry
- 4.2.5 Threat of Substitutes
4.3 Ecosystem Analysis
- 4.3.1 Raw Material Suppliers
- 4.3.2 Manufacturers
- 4.3.3 Distributors/Suppliers
- 4.3.4 End Users
5. South and Central America RNAi Therapeutics Market – Key Market Dynamics
5.1 Growth Drivers
- 5.1.1 RNAi Therapeutics in Cancer Therapy
5.2 Market Opportunities
- 5.2.1 Imaging Modalities for RNAi Therapeutics for RNAi Therapeutics
5.3 Future Trends
- 5.3.1 Rising Research & Development (R&D) activity
5.4 Impact of Drivers and Restraints
6. South and Central America RNAi Therapeutics Market Regional Analysis
6.1 South and Central America RNAi Therapeutics Market Overview
6.2 South and Central America RNAi Therapeutics Market Revenue 2017-2027 (US$ Million)
6.3 South and Central America RNAi Therapeutics Market Forecast Analysis
7. South and Central America RNAi Therapeutics Market Analysis – by Molecule Type
7.1 Small Interfering RNAs
- 7.1.1 Overview
- 7.1.2 Small Interfering RNAs: South and Central America RNAi Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
7.2 MicroRNA
- 7.2.1 Overview
- 7.2.2 MicroRNA: South and Central America RNAi Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
8. South and Central America RNAi Therapeutics Market Analysis – by Application
8.1 Genetic Disorders
- 8.1.1 Overview
- 8.1.2 Genetic Disorders: South and Central America RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
8.2 Oncology
- 8.2.1 Overview
- 8.2.2 Oncology: South and Central America RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
8.3 Neurodegenerative Disorders
- 8.3.1 Overview
- 8.3.2 Neurodegenerative Disorders: South and Central America RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
8.4 Cardiovascular
- 8.4.1 Overview
- 8.4.2 Cardiovascular: South and Central America RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
8.5 Respiratory Disorders
- 8.5.1 Overview
- 8.5.2 Respiratory Disorders: South and Central America RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
8.6 Infectious Diseases
- 8.6.1 Overview
- 8.6.2 Infectious Diseases: South and Central America RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
8.7 Renal Diseases
- 8.7.1 Overview
- 8.7.2 Renal Diseases: South and Central America RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
9. South and Central America RNAi Therapeutics Market Analysis – by Route of Administration
9.1 Intradermal Injections
- 9.1.1 Overview
- 9.1.2 Renal Diseases: South and Central America RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
9.2 Pulmonary Delivery
- 9.2.1 Overview
- 9.2.2 Renal Diseases: South and Central America RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
9.3 Intravenous Injections
- 9.3.1 Overview
- 9.3.2 Renal Diseases: South and Central America RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
9.4 Intraperitoneal Injections
- 9.4.1 Overview
- 9.4.2 Renal Diseases: South and Central America RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
10. South and Central America RNAi Therapeutics Market – South and Central America Analysis
10.1 South and Central America
- 10.1.1 South and Central America RNAi Therapeutics Market Breakdown, by Key
Country, 2020 and 2027 (%)
- 10.1.1.1 South and Central America RNAi Therapeutics Market – Revenue and
Forecast Analysis – by Country
- 10.1.1.1 Brazil:
South and Central America RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
- 10.1.1.1.1 Brazil: South and Central America RNAi Therapeutics Market Breakdown, by Molecule Type
- 10.1.1.1.2 Brazil: South and Central America RNAi Therapeutics Market Breakdown, by Application
- 10.1.1.1.3 Brazil: South and Central America RNAi Therapeutics Market Breakdown, by Route of Administration
- 10.1.1.2 Argentina:
South and Central America RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
- 10.1.1.2.1 Argentina: South and Central America RNAi Therapeutics Market Breakdown, by Molecule Type
- 10.1.1.2.2 Argentina: South and Central America RNAi Therapeutics Market Breakdown, by Application
- 10.1.1.2.3 Argentina: South and Central America RNAi Therapeutics Market Breakdown, by Route of Administration
- 10.1.1.3 Rest of South and Central America :
South and Central America RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
- 10.1.1.3.1 Rest of South and Central America : South and Central America RNAi Therapeutics Market Breakdown, by Molecule Type
- 10.1.1.3.2 Rest of South and Central America : South and Central America RNAi Therapeutics Market Breakdown, by Application
- 10.1.1.3.3 Rest of South and Central America : South and Central America RNAi Therapeutics Market Breakdown, by Route of Administration
11. Competitive Landscape
11.1 Heat Map Analysis
11.2 Company Positioning and Concentration
12. South and Central America RNAi Therapeutics Market Industry Landscape
12.1 Overview
12.2 Mergers and Acquisitions
12.3 Agreements, Collaborations, and Joint Ventures
12.4 New Product Launches
12.5 Expansions and Other Strategic Developments
13. Company Profiles
13.1 Quark
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Rexahn Pharmaceuticals, Inc
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Arbutus Biopharma
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Alnylam Pharmaceuticals, Inc
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 Arrowhead Pharmaceuticals, Inc.
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
14. Appendix
14.1 About Business Market Insights
Get Free Sample For South and Central America RNAi Therapeutics Market
